Data compression startup PetaGene has closed a significant contract with biopharma company Romulus Capital, attracting £2.1 million in funding from that organisation and several other investors based in Silicon Valley and London. This investment round brings PetaGene’s total funding to $3.2 million.

The new funding will help the company to grow its Cambridge technical team and global sales team, and further expand product offerings.

Romulus Capital is an early stage VC fund founded out of MIT in 2008. Its main goals are building technology and science-based companies with products which solve real issues in large traditional industries, or deep tech companies which have spun out of top-tier research groups.

More on these topics